Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves 1st at-home flu vaccine in U.S., a nasal spray
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider,
With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17.
FDA approves ‘FluMist,' says no healthcare provider needed
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the regulator said.
20h
AstraZeneca PLC ADR falls Friday, underperforms market
The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...
1d
AstraZeneca: Poised for Growth with Promising Innovation Pipeline and Attractive Valuation
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
FierceBiotech
7d
ESMO: AstraZeneca steps out from Daiichi's shadow, posting data on ADC rivals to AbbVie, Pfizer
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
1d
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
STAT
5d
News from ESMO: An AstraZeneca win in bladder cancer, and more
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
5d
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
2d
Highlighting the importance of Blood Donation with The American Red Cross & AstraZeneca
September is Blood Cancer Awareness Month and today we're at AstraZeneca's campus in Gaithersburg where they are co-hosting a ...
STAT
6d
AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study
If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...
11d
AstraZeneca stock drops after lung cancer drug trial setback
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
1d
AstraZeneca India to launch Palivizumab in Oct 2024, stocks trade flat
AstraZeneca Pharma India to launch Palivizumab in India, a drug to prevent RSV in high-risk children. Stocks rise.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
FluMist
Dow Jones Industrial Average
Trade
Food and Drug Administration
ADR
Feedback